A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children

Inclusion Criteria: * A male or female between (and including) 18 months to 47 months of age. * Written informed consent obtained from the parent/legal guardian of the subject. * Free of obvious health problems as established by medical history and/or clinical examination before entering the study Exclusion Criteria: * Seropositive for anti-HAV antibodies (\>=10 mIU/ml). * Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and safety follow-up. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose (for corticosteroids, such as prednisone, or equivalent, \>=0.5 mg/kg/day. * Inhaled and local steroids are allowed.) * Planned administration/ administration of a measles containing vaccine within 4 weeks prior to and after the first or booster dose of study vaccine. * Previous vaccination against hepatitis A. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * Major congenital defects or serious chronic illness. * Acute disease at the time of enrolment